BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 28264157)

  • 1. Unveiling the in Vivo Protein Corona of Circulating Leukocyte-like Carriers.
    Corbo C; Molinaro R; Taraballi F; Toledano Furman NE; Hartman KA; Sherman MB; De Rosa E; Kirui DK; Salvatore F; Tasciotti E
    ACS Nano; 2017 Mar; 11(3):3262-3273. PubMed ID: 28264157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the protein corona on liposome-liposome and liposome-cell interactions.
    Corbo C; Molinaro R; Taraballi F; Toledano Furman NE; Sherman MB; Parodi A; Salvatore F; Tasciotti E
    Int J Nanomedicine; 2016; 11():3049-63. PubMed ID: 27445473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein Nanoparticle Charge and Hydrophobicity Govern Protein Corona and Macrophage Uptake.
    Pustulka SM; Ling K; Pish SL; Champion JA
    ACS Appl Mater Interfaces; 2020 Oct; 12(43):48284-48295. PubMed ID: 33054178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nano-Bio Interactions in Cancer: From Therapeutics Delivery to Early Detection.
    Liu Y; Wang J; Xiong Q; Hornburg D; Tao W; Farokhzad OC
    Acc Chem Res; 2021 Jan; 54(2):291-301. PubMed ID: 33180454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How Corona Formation Impacts Nanomaterials as Drug Carriers.
    Gupta MN; Roy I
    Mol Pharm; 2020 Mar; 17(3):725-737. PubMed ID: 31939673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vivo Biomolecule Corona around Blood-Circulating, Clinically Used and Antibody-Targeted Lipid Bilayer Nanoscale Vesicles.
    Hadjidemetriou M; Al-Ahmady Z; Mazza M; Collins RF; Dawson K; Kostarelos K
    ACS Nano; 2015 Aug; 9(8):8142-56. PubMed ID: 26135229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuning liposome composition to modulate corona formation in human serum and cellular uptake.
    Yang K; Mesquita B; Horvatovich P; Salvati A
    Acta Biomater; 2020 Apr; 106():314-327. PubMed ID: 32081780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corona Composition Can Affect the Mechanisms Cells Use to Internalize Nanoparticles.
    Francia V; Yang K; Deville S; Reker-Smit C; Nelissen I; Salvati A
    ACS Nano; 2019 Oct; 13(10):11107-11121. PubMed ID: 31525954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Protein Corona of Plant Virus Nanoparticles Influences their Dispersion Properties, Cellular Interactions, and In Vivo Fates.
    Pitek AS; Wen AM; Shukla S; Steinmetz NF
    Small; 2016 Apr; 12(13):1758-69. PubMed ID: 26853911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposome protein corona characterization as a new approach in nanomedicine.
    Capriotti AL; Cavaliere C; Piovesana S
    Anal Bioanal Chem; 2019 Jul; 411(19):4313-4326. PubMed ID: 30758528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug delivery.
    Martinez JO; Molinaro R; Hartman KA; Boada C; Sukhovershin R; De Rosa E; Kirui D; Zhang S; Evangelopoulos M; Carter AM; Bibb JA; Cooke JP; Tasciotti E
    Theranostics; 2018; 8(4):1131-1145. PubMed ID: 29464004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unveiling the pitfalls of the protein corona of polymeric drug nanocarriers.
    Berrecoso G; Crecente-Campo J; Alonso MJ
    Drug Deliv Transl Res; 2020 Jun; 10(3):730-750. PubMed ID: 32152965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Super-Resolution Microscopy Unveils Dynamic Heterogeneities in Nanoparticle Protein Corona.
    Feiner-Gracia N; Beck M; Pujals S; Tosi S; Mandal T; Buske C; Linden M; Albertazzi L
    Small; 2017 Nov; 13(41):. PubMed ID: 28922574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro in-vivo correlation (IVIVC) in nanomedicine: Is protein corona the missing link?
    Jain P; Pawar RS; Pandey RS; Madan J; Pawar S; Lakshmi PK; Sudheesh MS
    Biotechnol Adv; 2017 Nov; 35(7):889-904. PubMed ID: 28844973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ analysis of liposome hard and soft protein corona structure and composition in a single label-free workflow.
    Kari OK; Ndika J; Parkkila P; Louna A; Lajunen T; Puustinen A; Viitala T; Alenius H; Urtti A
    Nanoscale; 2020 Jan; 12(3):1728-1741. PubMed ID: 31894806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How protein coronas determine the fate of engineered nanoparticles in biological environment.
    Capjak I; Goreta SŠ; Jurašin DD; Vrček IV
    Arh Hig Rada Toksikol; 2017 Dec; 68(4):245-253. PubMed ID: 29337683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles.
    Hadjidemetriou M; Al-Ahmady Z; Kostarelos K
    Nanoscale; 2016 Apr; 8(13):6948-57. PubMed ID: 26961355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Situ Characterization of Protein Adsorption onto Nanoparticles by Fluorescence Correlation Spectroscopy.
    Shang L; Nienhaus GU
    Acc Chem Res; 2017 Feb; 50(2):387-395. PubMed ID: 28145686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functionalization of Liposomes with Hydrophilic Polymers Results in Macrophage Uptake Independent of the Protein Corona.
    Weber C; Voigt M; Simon J; Danner AK; Frey H; Mailänder V; Helm M; Morsbach S; Landfester K
    Biomacromolecules; 2019 Aug; 20(8):2989-2999. PubMed ID: 31268685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clusterin in the protein corona plays a key role in the stealth effect of nanoparticles against phagocytes.
    Aoyama M; Hata K; Higashisaka K; Nagano K; Yoshioka Y; Tsutsumi Y
    Biochem Biophys Res Commun; 2016 Nov; 480(4):690-695. PubMed ID: 27983983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.